加载中
NASDAQHealthcareMedical - Devices
最新数据
US$68.15
+US$2.41 · +3.67%
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
常规交易时段
US$68.18
+US$2.44 · +3.71%
盘中时间采用ET。市场数据可能有所延迟。
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
日内区间
当前US$68.18
52周区间
当前US$68.18
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
84
深度低估
情绪
63
看涨
风险
34
中等风险
动量
34
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
日内区间
当前US$68.18
52周区间
当前US$68.18
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 206.25亿 USD | 196.72亿 USD | 195.52亿 USD | 183.41亿 USD | 175.85亿 USD |
| 销货成本 | 123.78亿 USD | 114.67亿 USD | 116.3亿 USD | 111.62亿 USD | 104.11亿 USD |
| 毛利 | 82.47亿 USD | 82.05亿 USD | 79.22亿 USD | 71.79亿 USD | 71.74亿 USD |
| 研究与开发 | 12.6亿 USD | 13.11亿 USD | 12.05亿 USD | 10.26亿 USD | 8.16亿 USD |
| 销售、一般及管理费用 | 42.25亿 USD | 42.69亿 USD | 42.82亿 USD | 36.31亿 USD | 35.63亿 USD |
| 营业费用 | 54.85亿 USD | 55.8亿 USD | 54.87亿 USD | 46.57亿 USD | 43.79亿 USD |
| 利息收入 | — | — | 2600万 USD | — | 3400万 USD |
| 利息支出 | 4.5亿 USD | 5.05亿 USD | 5.42亿 USD | 8600万 USD | 4000万 USD |
| 折旧和摊销 | 5.78亿 USD | 5.8亿 USD | 6.1亿 USD | 6.33亿 USD | 6.25亿 USD |
| 营业利润 | 27.62亿 USD | 26.25亿 USD | 24.35亿 USD | 25.22亿 USD | 27.95亿 USD |
| 净利润 | 20.84亿 USD | 19.93亿 USD | 15.68亿 USD | 19.16亿 USD | 22.47亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$80.50
上涨空间 18.07%年度分割调整后的每股现金分配。
US$0.14
2025年（完整年度）+16.7% 自从 2024
2026年（部分年度）：US$0.105
US$0.12
2,024
US$0.14
2,025
US$0.105
2,026*
* 在现有股息历史记录中，该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息即将实施 | 2026年10月23日 | US$0.04Quarterly | 2026年10月23日 | 2026年11月13日 |
股息 | 2026年7月24日 | US$0.035Quarterly | 2026年7月24日 | 2026年8月14日 |
股息 | 2026年4月2日 | US$0.035Quarterly | 2026年4月3日 | 2026年5月15日 |
股息 | 2026年1月9日 | US$0.035Quarterly | 2026年1月9日 | 2026年2月13日 |
股息 | 2025年10月24日 | US$0.035Quarterly | 2025年10月24日 | 2025年11月14日 |
股息 | 2025年7月25日 | US$0.035Quarterly | 2025年7月25日 | 2025年8月15日 |
除息 2026年10月23日
US$0.04
Quarterly
2026年10月23日登记 · 支付日 2026年11月13日
除息 2026年7月24日
US$0.035
Quarterly
2026年7月24日登记 · 支付日 2026年8月14日
除息 2026年4月2日
US$0.035
Quarterly
2026年4月3日登记 · 支付日 2026年5月15日
除息 2026年1月9日
US$0.035
Quarterly
2026年1月9日登记 · 支付日 2026年2月13日
除息 2025年10月24日
US$0.035
Quarterly
2025年10月24日登记 · 支付日 2025年11月14日
除息 2025年7月25日
US$0.035
Quarterly
2025年7月25日登记 · 支付日 2025年8月15日
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T571.91亿0.04%129.43万亿 JPY0.09%JP¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI10.3亿0.04%2.3万亿 USD0.03%US$381.48-0.12%
Vanguard S&P 500 ETFVOO8.61亿0.05%1.8万亿 USD0.03%US$714.91-0.10%
Vanguard Morningstar Mid-Cap ETFVO7.01亿0.31%2264亿 USD0.03%US$80.965-0.22%
Invesco QQQ Trust, Series 1QQQ6.19亿0.12%5060.67亿 USD0.18%US$746.16-0.68%
iShares Core S&P 500 ETFIVV3.95亿0.04%8964.4亿 USD0.03%US$781.24-0.09%
State Street SPDR S&P 500 ETFSPY3.6亿0.04%8172亿 USD0.09%US$777.77-0.10%
Vanguard Morningstar Value ETFVTV3.1亿0.12%2624亿 USD0.03%US$221.36+0.35%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Mid-Cap ETFVOInvesco QQQ Trust, Series 1QQQiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
